Quantifying the Benefits of Genome-Driven Oncology.
Overview
abstract
-
The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. Cancer Discov; 7(6); 552-4. ©2017 AACR.See related article by Massard et al., p. 586.
publication date
published in
Research
keywords
Identity
PubMed Central ID
Scopus Document Identifier
Digital Object Identifier (DOI)
-
10.1158/2159-8290.CD-17-0380
PubMed ID
Additional Document Info
has global citation frequency
volume
issue